Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-26 @ 3:14 PM
NCT ID:
NCT07391761
Brief Summary:
The purpose of this study is to evaluate:
* What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan?
* What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan?
* What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?
Detailed Description:
This study is seeking participants who:
* have relapsed or refractory multiple myeloma (RRMM),
* have received at least four prior lines of therapy (including a PI, an IMiD, and an anti-CD38 antibody),
* are 18 years or older.
Participants receive elranatamab according to the approved label in Taiwan and continue treatment until disease progression or discontinuation. The study will evaluate real-world effectiveness and describe patient characteristics and treatment patterns to better understand elranatamab use in routine care.
Study:
NCT07391761
Study Brief:
Protocol Section:
NCT07391761